Last reviewed · How we verify
Twinrix™ Adult
Twinrix is a combined vaccine that stimulates the immune system to produce antibodies against both hepatitis A and hepatitis B viruses.
Twinrix is a combined vaccine that stimulates the immune system to produce antibodies against both hepatitis A and hepatitis B viruses. Used for Prevention of hepatitis A infection in adults ≥18 years, Prevention of hepatitis B infection in adults ≥18 years.
At a glance
| Generic name | Twinrix™ Adult |
|---|---|
| Also known as | Combined hepatitis A and B vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated viral vaccine (combination) |
| Target | Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Twinrix contains inactivated hepatitis A virus and recombinant hepatitis B surface antigen (HBsAg) that trigger adaptive immune responses. Upon vaccination, the body produces specific antibodies and cellular immunity against both pathogens, providing protection against infection with either virus. The combination vaccine simplifies immunization schedules by delivering both vaccines in a single formulation.
Approved indications
- Prevention of hepatitis A infection in adults ≥18 years
- Prevention of hepatitis B infection in adults ≥18 years
Common side effects
- Injection site soreness or pain
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™ (PHASE4)
- Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule (PHASE3)
- Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared (PHASE3)
- Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults (PHASE3)
- Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 (PHASE3)
- Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule (PHASE3)
- Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years (PHASE3)
- Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Twinrix™ Adult CI brief — competitive landscape report
- Twinrix™ Adult updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI